Lv11
40 积分 2025-09-23 加入
Stem-Cell Aging and Pathways to Precancer Evolution
3小时前
待确认
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
12天前
已完结
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
2个月前
已完结
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study
3个月前
已关闭
Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer
3个月前
已关闭
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
3个月前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
3个月前
已完结
Pembrolizumab for Early Triple-Negative Breast Cancer
3个月前
已完结
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
3个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
3个月前
已完结
皖公网安备34019202002308
